DeNovaMed

Additional Q4 2024 Press Coverage of DeNovaMed Antibiotic Programs

Uncategorized

Media release: Dalhousie University researchers, DeNovaMed Inc. develop new family of antibiotics that could treat multidrug‑resistant bacterial ‘superbugs’

Nov 28, 2024 – For the first time in over 30 years, researchers at Dalhousie University, DeNovaMed Inc. and the University of Toronto have developed a new family of antibiotics to treat multidrug-resistant bacteria, addressing a concern the World Health Organization has identified as one of the three greatest threats to human health. Antimicrobial medicines

Media release: Dalhousie University researchers, DeNovaMed Inc. develop new family of antibiotics that could treat multidrug‑resistant bacterial ‘superbugs’ Read More »

DeNovaMed DNM0547 Program Published in Nature Communications

DeNovaMed’s groundbreaking research into novel antibiotics is now a published article in the prestigious journal Nature Communications! In this article, DeNovaMed scientists and collaborators summarize progress on the design and optimization of hundreds of novel compounds against ACP synthase (AcpS), culminating in preclinical candidate DNM0547. The article surveys the enabling data for DNM0547 and concludes

DeNovaMed DNM0547 Program Published in Nature Communications Read More »

Scroll to Top